GIOSTAR CEO and Co-Founder Deven Patel spoke on the most downloaded episode of the “Exploring Leadership” podcast, hosted by military veteran Spence Taylor
GIOSTAR has continuously set the bar for innovation in cancer research. The firm was recently recognized with a prestigious award, given to only 9 other researchers.
Chronic liver disorders (CLDs) affect roughly 844 million people worldwide, and result in the deaths of about two million people each year. GIOSTAR recently conducted research pointing to the potential benefit of stem cell therapy in addressing this epidemic.
Stem cell therapy has applications that extend beyond traditional disorders (i.e., orthopedic injuries), including skin care. In this blog post, we review the potential benefits of stem cells on wrinkles, acne, psoriasis, and other conditions, and clear up common misconceptions.
Scientific Review: Stem Cells Therapy as a Possible Therapeutic Option in Treating COVID-19 Patients
GIOSTAR leaders recently wrote on the potential benefits of stem cells in combating COVID-19. Published in Stem Cell Reviews and Reports, the review was written by Drs. Anand Srivastava, Prabhat Soni, Diana Esquivel, Rangnath Mishra, Rajasekar Seetharaman, and Anjum Mahmood
GIOSTAR recently treated a patient suffering from COVID-19 with stem cells. He experienced considerable improvement following this procedure. A placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.
Dr. Anand Srivastava, Deven Patel, Dr. Amy Killen, and Dr. Kyle Bergquist take part in a fascinating mini-documentary entitled Age of Cells. The program features extensive interviews with Dr. Srivastava and Mr. Patel, excerpts from lectures, and a sweeping tour of India.
Learn more about multiple sclerosis, and how stem cell therapy may provide symptomatic relief for patients suffering from this neurodegenerative disease.
GIOSTAR Chairman and Co-Founder Dr. Anand Srivastava recently spoke with Healthcare Weekly about stem cells, COVID-19, and numerous other topics.